Description

Simple

A cancer chemotherapy medication used to treat advanced stages of colon and rectal cancer.

Clinical

A folate analog thymidylate synthase inhibitor used in the treatment of advanced colorectal cancer.

Overview

Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.

Pharmacology

Indication

For the treatment of malignant neoplasm of colon and rectum

Pharmacodynamic

Raltitrexed belongs to a group of medicines known as antimetabolites. It is used to treat cancer of the colon and rectum. It may also be used to treat other kinds of cancer, as determined by your doctor. Raltitrexed blocks an enzyme needed by the cell to live. This interferes with the growth of canc... Read more

Mechanism of action

Raltitrexed is an antineoplastic Agents and folic acid antagonists. Raltitrexed inhibits thymidylate synthase (TS) leading to DNA fragmentation and cell death. It is transported into cells via a reduced folate carrier. Inside the cell Raltitrexed is extensively polyglutamated, which enhances thymidy... Read more

Absorption

Information currently not available.

Protein binding

>93%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

198 hours

Route of elimination

Information currently not available.

Toxicity

Side effects include pale skin, troubled breathing, unusual bleeding or bruising, unusual tiredness or weakness, black, tarry stools, chest pain, chills, cough, fever, painful or difficult urination, shortness of breath, sore throat, sores, ulcers, or white spots on lips or in mouth, swollen glands,... Read more

Adverse Effects

Contraindications

  • Regions: Canada
  • Age Groups:
    • children
  • Regions: Canada
  • Patient Conditions:
      • Name: Pregnancy
      • Drugbank Id: DBCOND0018394
  • Regions: Canada
  • Patient Conditions:
      • Name: Severe Renal Impairment
      • Drugbank Id: DBCOND0045819
      • Modification Of:
        • Base:
          • Name: Renal Impairment
          • Drugbank Id: DBCOND0031781
        • Severity:
          • Includes:
            • severe
  • Regions: Canada
  • Patient Conditions:
      • Name: Severe Hepatic Impairment
      • Drugbank Id: DBCOND0070791
      • Modification Of:
        • Base:
          • Name: Heptic Impairment
          • Drugbank Id: DBCOND0072269
        • Severity:
          • Includes:
            • severe

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Raltitrexed
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(6R)-Folinic acid
The therapeutic efficacy of Raltitrexed can be decreased when used in combination with (6R)-Folinic acid.
(6S)-5,6,7,8-tetrahydrofolic acid
The therapeutic efficacy of Raltitrexed can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.
(R)-warfarin
The risk or severity of bleeding can be increased when (R)-warfarin is combined with Raltitrexed.
(S)-Warfarin
The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Raltitrexed.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Raltitrexed is combined with 2-Methoxyethanol.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Raltitrexed.
5-methyltetrahydrofolic acid
The therapeutic efficacy of Raltitrexed can be decreased when used in combination with 5-methyltetrahydrofolic acid.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Raltitrexed is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Abatacept.
Abciximab
The risk or severity of bleeding can be increased when Abciximab is combined with Raltitrexed.
Abetimus
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Abetimus.
Acenocoumarol
The risk or severity of bleeding can be increased when Acenocoumarol is combined with Raltitrexed.
Acetylsalicylic acid
The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Raltitrexed.
Acteoside
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Acteoside.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Raltitrexed.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Raltitrexed.
Afelimomab
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Afelimomab.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Raltitrexed.
Aldosterone
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Aldosterone.
Alefacept
The risk or severity of adverse effects can be increased when Alefacept is combined with Raltitrexed.